Followers | 437 |
Posts | 42954 |
Boards Moderated | 2 |
Alias Born | 05/08/2006 |
Friday, June 21, 2013 11:09:58 AM
VentriPoint Diagnostics has designed a heart visualization system designed to benefit doctors, patients, and the overall healthcare industry by reducing time and costs of the procedure. The system uses a 2D echo to make a 3D model of the heart to evaluate right heart function and get the same information obtained from an MRI, but in a fraction of the time.
As company CEO George Adams recently stated in an interview, the biggest beneficiary of the system is the patient. While cardiac MRIs can take anywhere between 30-90 minutes and take up to three months to get results, with VentriPoint’s VMS™ system the procedure is done within 10 minutes producing immediate results. This time advantage is especially significant for children and adults who have a hard time lying still or are anxious within confined spaces, as is necessary with traditional MRI procedures.
VentriPoint has already installed the system at multiple sites in the United States and overseas, and has received positive feedback across the board.
“The VMS is non-invasive and repeatable as compared to MRI, and we are confident in the results using routine clinical scanning. At Evelina, all children undergoing MRI must have a general anesthetic. This is not required for the VMS and is a major improvement as we will not have to subject these children to the added complexity and risk of a general anesthetic.” —John Simpson, MD, director of the Echocardiography Laboratory at Evelina Hospital in London, UK.
As of now, the VMS™ is for investigational use only in the United States and has been approved for clinical use in Canada and Europe. VentriPoint in April received from the U.S. FDA a request for additional information as the agency completes the review of Pulmonary Arterial Hypertension (PAH) 510(k). The company must now show the FDA that its technology works as well as MRI, as has already been demonstrated in other parts of the world.
“The VentriPoint system combines the best of both worlds: the ease and availability of 2D echo and the intrinsic 3D information of the MRI acquired shapes of the right ventricle in the database. We anticipate a reduction of the need for (expensive) cardiac Magnetic Resonance Imaging (MRI) for the purpose of assessment of right ventricle volumes.” —Willem Helbing MD, head of Pediatric Cardiology at Erasmus Sophia Children’s Hospital in Rotterdam, Netherlands.
For more information, visit www.ventripoint.com
Recent VPTDF News
- Will Shares Rise on Milestone Development for AI-Powered Heart Technology? • AllPennyStocks.com • 05/06/2024 01:50:00 PM
- Healthcare Stock Rallies Strongly Following Key Implementation • AllPennyStocks.com • 12/12/2023 06:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM